Form 4: ClearPoint Neuro CEO Joseph Burnett Awarded Restricted Stock Units

ClearPoint Neuro's CEO, Joseph Burnett, received 132,841 restricted stock units (RSUs) on March 3, 2025, vesting over a three-year period.

Summary

• On March 3, 2025, Joseph Michael Burnett, CEO and President of ClearPoint Neuro, Inc., was granted 132,841 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of CLPT common stock per unit.
• The RSUs will vest in three tranches: 20% on March 3, 2026, 40% on March 3, 2027, and the remaining 40% on March 3, 2028.
• A Power of Attorney is in place, authorizing Danilo D'Alessandro to act on behalf of Joseph M. Burnett in matters related to SEC filings.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a standard practice and signals confidence in the CEO's continued leadership. The vesting schedule aligns interests with shareholders.

Positives

• The grant of restricted stock units aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the CEO over the next three years.

Future Outlook

The vesting schedule of the RSUs suggests an expectation of continued leadership and value creation by the CEO over the next three years.

Industry Context

Grants of restricted stock units are a common practice in the biotechnology and medical device industries to incentivize and retain key executives.

Comparison to Industry Standards

• Executive compensation packages, including RSU grants, are common in publicly traded companies, particularly in growth-oriented sectors like medical technology.
• The size and vesting schedule of the RSU grant would typically be benchmarked against peer companies of similar size and stage of development, such as those in the Russell 2000 index or specific medtech industry indices.
• Companies like Medtronic, Stryker, and Boston Scientific also utilize equity-based compensation, but their executive compensation structures are likely more complex due to their larger size and global operations.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the CEO's interests with long-term value creation.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates